caa a22 4500 606156119 CHVBK 20210128100607.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s10096-015-2372-3 doi (NATIONALLICENCE)springer-10.1007/s10096-015-2372-3 Statins can increase the risk of herpes zoster infection in Asia [Elektronische Daten] [H.-H. Chen, C.-L. Lin, C.-J. Yeh, S.-Y. Yeh, C.-H. Kao] This study evaluated whether statin therapy increases the risk of herpes zoster (HZ) infection in Asia. This retrospective cohort study used the Longitudinal Health Insurance Database (LHID2000). From the LHID2000, patients aged 20years were divided into two cohorts according to their statin use and were matched at a 1:1 ratio according to propensity scores, which were calculated using a logistic regression for estimating the probability of treatment assignment. The primary outcome was HZ infection. All patients were followed from the index date until the date of HZ infection, withdrawal from the insurance system, or the end of 2011. The study included 53,069 patients receiving statin therapy as a statin cohort and 53,069 patients without statin therapy as a nonstatin cohort. The mean follow-up durations for the statin cohort and nonstatin cohort were 4.89 [standard deviation (SD) = 2.86] years and 4.75 (SD = 2.90) years, respectively. The patients in the statin cohort had a 21% higher risk of contracting HZ infection than the patients in the nonstatin cohort [95% confidence interval (CI) = 1.13-1.29]. The incidence of HZ infection increased with the Charlson comorbidity index (CCI) score in both cohorts. A high mean defined daily dose of the six types of statins considered in this study was associated with a significantly increased risk of HZ infection. Statin therapy can increase HZ infection in Asia. More benefit-risk evaluations for statin use are necessary in Asia. Springer-Verlag Berlin Heidelberg, 2015 Chen H.-H Institute of Medicine and Public Health, Chung Shan Medical University, Taichung, Taiwan aut Lin C.-L Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan aut Yeh C.-J Institute of Medicine and Public Health, Chung Shan Medical University, Taichung, Taiwan aut Yeh S.-Y Nantou Christian Hospital, Nantou, Taiwan aut Kao C.-H Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/7(2015-07-01), 1451-1458 0934-9723 34:7<1451 2015 34 10096 https://doi.org/10.1007/s10096-015-2372-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-015-2372-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chen H.-H Institute of Medicine and Public Health, Chung Shan Medical University, Taichung, Taiwan aut NATIONALLICENCE 700 1- Lin C.-L Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan aut NATIONALLICENCE 700 1- Yeh C.-J Institute of Medicine and Public Health, Chung Shan Medical University, Taichung, Taiwan aut NATIONALLICENCE 700 1- Yeh S.-Y Nantou Christian Hospital, Nantou, Taiwan aut NATIONALLICENCE 700 1- Kao C.-H Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/7(2015-07-01), 1451-1458 0934-9723 34:7<1451 2015 34 10096